Clinical trials: Pemphigus
Pemphigus Vulgaris
Identifying Factors Influencing In-Hospital Relapse in Pemphigus Patients
The objective of this retrospective study was to investigate the factors influencing in-hospital relapse during acute episodes of pemphigus, an autoimmune blistering disease characterized by self-antibodies targeting desmogleins.
- Trial name
- NCT06167408
- Where
- China
- Volunteers
- 96 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Pemphigus, Dermatological Disease
Identification of Vulnerability Factors in the Course of Pemphigus Patients
The bullous pemphigoid treatment is based on corticosteroids continued for several years. Pemphigus causes some patients a psychological impact and sometimes major vulnerability that can occur not only at diagnosis but also at…
- Trial name
- SHS-Pemphigus (NCT02237313)
- Testing
- psychological support and therapeutic education program
- Where
- 9 sites in France
- Volunteers
- 48 people
- Sponsor
- University Hospital, Rouen
Pemphigus Vulgaris, Pemphigus Foliaceus
Autoimmune Blistering Diseases Study
Pemphigus and bullous pemphigoid (BP) are severe autoimmune blistering diseases (AIBD) that pose a critical need for new therapeutic approaches.
- Conditions
- Pemphigus Vulgaris, Pemphigus Foliaceus, Bullous Pemphigoid
- Trial name
- AIBD (NCT02753777)
- Testing
- Questionnaires
- Where
- 3 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of Pennsylvania
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
This is a randomized, multi-site, adaptive, open-label clinical trial comparing the immune response to different additional doses of COVID-19 vaccine in participants with autoimmune disease requiring IS medications.
- Conditions
- Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS)
- Trial name
- NCT05000216
- Testing
- Moderna mRNA-1273, BNT162b2, Ad26.COV2.S
- Where
- 29 sites in United States
- Volunteers
- 258 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pemphigus
European Trial of Adjuvant Oral Glucocorticoid Pulse Therapy in Pemphigus
By this study, the investigators want to test if the value of adjuvant pulse glucocorticoid therapy for pemphigus can be determined by comparing an experimental arm (dexamethasone pulse therapy, prednisolone, and azathioprine)…
- Trial name
- NCT00127764
- Testing
- dexamethasone (50mg 1dd6, 3 consecutive days/month)
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- University Medical Center Groningen
Pemphigus Vulgaris
Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus Vulgaris
The purpose of this 12-month study was to determine the efficacy of dapsone as a glucocorticoid-sparing agent in maintenance phase pemphigus vulgaris.
- Trial name
- NCT00429533
- Testing
- Dapsone
- Where
- 8 sites in United States
- Volunteers
- 48 people
- Sponsor
- Jacobus Pharmaceutical
Pemphigus Vulgaris
Azathioprine Versus Placebo in Pemphigus Vulgaris Treated With Prednisolone
Description: Pemphigus vulgaris is an autoimmune, chronic and recurrent blistering disease with unknown etiology that affects mucosa and skin of patients with significant morbidity and mortality.
- Trial name
- NCT00626678
- Testing
- Azathioprine, Prednisone
- Where
- Iran
- Volunteers
- 48 people
- Sponsor
- Tehran University of Medical Sciences
Inherited Epidermolysis Bullosa, Ichthyosis
FARD (RaDiCo Cohort) (RaDiCo-FARD)
The goal of this observational study is to conduct a prospective assessment of the individual Burden of 9 rare skin diseases to assess disability in the broadest sense of the term (psychological, social, economic and physical)…
- Conditions
- Inherited Epidermolysis Bullosa, Ichthyosis, Ectodermal Dysplasia, Incontinentia Pigmenti
- Trial name
- FARD (NCT05954416)
- Where
- 15 sites in France
- Volunteers
- 900 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Pemphigus
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus
Pemphigus is a rare acquired autoimmune disease in which immunoglobulin G (IgG) antibodies target desmosomal proteins to produce intraepithelial, and mucocutaneous blisters.
- Trial name
- NCT04400994
- Testing
- Rituximab, IVIg
- Where
- Hong Kong
- Volunteers
- 20 people
- Sponsor
- The University of Hong Kong
Pemphigus Vulgaris
A Study to Evaluate Efficacy and Safety of Abatacept in Participants of Pemphigus Vulgaris (PV)
Pemphigus vulgaris (PV) is a rare, chronic, debilitating, and potentially life-threatening autoimmune disorder that is characterized by mucocutaneous blisters.Abatacept is a biologic drug that belongs to the class of T-cell…
- Trial name
- NCT05303272
- Testing
- Abatacept Prefilled Syringe, Mycophenolate Mofetil 500Mg Tab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tongji Hospital
Pemphigus Vulgaris (PV)
A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
This study was designed to assess the efficacy and safety of CellCept (1 g or 1.5 g orally twice daily for 52 weeks) in patients with pemphigus vulgaris receiving prednisone or other corticosteroids.
- Trial name
- NCT00683930
- Testing
- Mycophenolate Mofetil 2 g/Day, Mycophenolate Mofetil (MMF) 3 g/Day
- Where
- 26 sites in United States, Canada and 6 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Pemphigus
Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris
This study is designed as a multi-country, multicenter, open label extension to Phase III trial OPV116910. The primary objective is to provide continued treatment with ofatumumab subcutaneous (SC) for eligible subjects who…
- Trial name
- NCT02613910
- Testing
- Ofatumumab, Acetaminophen/paracetamol, Antihistamine (cetirizine or equivalent)
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Pemphigus Disease
Comparison Between Rituximab Treatment and General Corticotherapy Treatment in Patients With Pemphigus
Pemphigus is a severe and sometimes life-threatening disease with a mortality rate between 5 and 10 percent depending on the severity of disease and age of patients.
- Trial name
- Rituximab 3 (NCT00784589)
- Testing
- General Corticotherapy, Rituximab
- Where
- France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Rouen
Pemphigus
Effect of Anti CD20 in Pemphigus Desease
to treat in an open non comparative clinical study patients presenting pemphigus with corticodependance, corticoresistance and contre-indication to systemic steroids.
- Trial name
- NCT00213512
- Testing
- Mabthera
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Rouen
Type 2 Inflammatory Disorders
Compassionate Use or Expanded Access of Dupilumab
Provide Compassionate Use or Expanded Access of Dupilumab
- Trial name
- NCT04776694
- Testing
- Dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Pemphigus
Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus
The purpose of this study is to compare the effectiveness of rituximab alone vs combination of rituximab and cyclophosphamide in the treatment of pemphigus not responding adequately to routine medications.
- Trial name
- NCT01974518
- Testing
- Rituximab and Cyclophosphamide IV
- Where
- 2 sites in India
- Volunteers
- 20 people
- Sponsor
- Uprety Shraddha
Pemphigus Vulgaris
A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)
This is a Phase III, randomized, double-blind, double-dummy, active-comparator, parallel-arm, multicenter study to evaluate the efficacy and safety of rituximab compared with MMF in participants with moderate-to-severely active…
- Trial name
- NCT02383589
- Testing
- Mycophenolate Mofetil, Rituximab
- Where
- 68 sites in United States, Argentina and 10 more
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
Pemphigus Vulgaris
Serum IL-21 Levels in Patients With Pemphigus Vulgaris
Pemphigus is severe antigen derived autoimmune bullous skin disorder, the word pemphigus is derived from the Greek word" pemphix " which means blister .
- Trial name
- NCT03177213
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Assiut University
Pemphigus Vulgaris
Efficacy of Interleukin-2 Gargle in the Treatment of Oral Mucosa Lesion in Pemphigus Vulgaris
This clinical study will test the short-term efficacy of interleukin-2 gargle combined with systemic use of glucocorticoids in the treatment of oral mucosal lesions in mucosal-dominant pemphigus vulgaris and moderate…
- Trial name
- NCT04023149
- Testing
- recombinant human interleukin-2 (rhIL-2)
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Second Xiangya Hospital of Central South University
Pemphigus Vulgaris, Pemphigus Foliaceus
A Study to Assess the Efficacy and Safety of a Subcutaneous Formulation of Efgartigimod PH20 SC in Adults With Pemphigus (Vulgaris or Foliaceus)
This is a prospective, multicenter, randomized, double-blinded, placebo-controlled trial to investigate the efficacy, safety, patient outcome measures, tolerability, immunogenicity, PK, and PD of efgartigimod PH20 SC in adult…
- Trial name
- ADDRESS (NCT04598451)
- Testing
- efgartigimod PH20 SC, prednisone
- Where
- 134 sites in United States, Australia and 19 more
- Volunteers
- 222 people
- Sponsor
- argenx